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Several phenothiazines and related compounds were synthesized and their antifungal activity was
evaluated in vitro. The results observed for a-chloro-N-acetyl phenothiazine led us to choose this
compound as a lead in the search of antifungal agents.
 2010 Elsevier Masson SAS. All rights reserved.1. Introduction
In recent years, the incidence and severity of fungal diseases has
increased, particularly in patients with impaired immunity [1]. The
growing number of cases of fungi involved in sepsis is a consistent
trend [2], being Candida the fourth most common isolate in noso-
comial bloodstream infections in some developed countries [3].
Furthermore, invasive candidiasis is a problem of growing impor-
tance in critically ill patients, such those in intensive care [4]. Besides,
the mortality rate due to invasive aspergillosis in neutropenic
patients has increased [5]. Superficial mycoses, such dermatophy-
tosis or either infections caused by non dermatophyte agents, are an
important cause of morbidity, being more severe in immunocom-
promised patients. Due to the increase in clinically important fungal
infections and the small number of available antifungal agents, as
well as to the appearance of antifungal resistance, searching for new,
more effective and less toxic drugs is mandatory [6].ology, Facultad de Farmacia y
CABA, Argentina.
le), amoglio@ffyb.uba.ar (A.G.
son SAS. All rights reserved.Phenothiazines and related compounds, including tranquilizers
[7] and drugs with anti-inflammatory [8], antimalarial [9], anti-
psychotic [10], antimicrobial [11], antitubercular [12,13], antitumor
[14e16], antihistaminic [17] and analgesic [18] properties, have
found widespread use in medicinal chemistry. Among these, those
that act as antihistaminic and antipsychotic agents are the ones
most exploited therapeutically. In these compounds, the amino
alkyl side chain connected to the nitrogen atom of the heterocyclic
unit plays a crucial role in their properties [19,20]. In the last
decade, the antifungal properties of some antipsychotic phenothi-
azine derivatives, such as trifluoroperazine, chlorpromazine and
fluphenazine, have been described (Chart 1) [21].
In the course of a research program in medicinal chemistry with
the aim to discover phenothiazines with antifungal action alone,
we evaluated pipothiazine (PIP), a neuroleptic phenothiazine,
promethazine (PMZ), an antihistaminic phenothiazine, and a series
of N-acyl and N-alkyl phenothiazine derivatives. Based on the
results observed when evaluating their antifungal activity, some N-
acyl compounds resulting from isosteric replacements and opening
or ring contraction in the phenothiazine core were prepared. Then,
with the battery of compounds available, we attempted to establish

























Chart 1. Structures of some antihistaminic and neuroleptic phenothiazines.
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We have previously described the synthesis of compound 1, as
starting material in the procedure to prepare the neuroleptic
compound PIP [22].
Compound 1, treated with b-Cl-propanoyl chloride, afforded
compound 2, which was reacted with the commercially available
compound 3, to give PIP (Scheme 1).
TheN-acyl derivatives 2 [22], 4 [22], 6 [23], 7 [24], and 8 (Chart 2)
were synthesized usingmicrowave irradiation (MW),with excellent
yield and very short times of reaction, starting from the corre-
sponding amines and using b-chloro propanoyl chloride (2, 4),
a-chloro acetyl chloride (6, 8) and acetyl chloride (7).
N-acyl derivatives 4 and 6 were transformed into the N-alkyl
compounds 5 and 9 [25] by reductionwith borane generated in situ
(Chart 3).
The N-acyl derivatives 10 and 11 [26] were also prepared using
MW starting from the corresponding amine and a-chloro acetyl
chloride. Compound 12 [27] was synthesized by a conventional
procedure using acetyl chloride and carbazole (commercial)
(Chart 4).
The nitro compound 13, previously prepared by us [22], was
reduced using Zn/CaCl2, affording compound 14. Treatment of this






Scheme 1. Reagents: (a) b-derivative 15, with good yield and very short time of reaction
(Scheme 2).
The spectroscopic behavior observed in the 1H-NMR spectra of
compounds 2 and 8 showed the diastereotopicity of the hydrogen
atoms attached to the methylene carbon in alpha position to the
carbonyl group [23], which would indicate the presence of chirality
in the phenothiazine system.
3. Results and discussion
Since the antifungal activity of PIP and PMZ commercially
available were evaluated, showed good agreement with that
previously described for trifluoperazine, chlorpromazine, and
fluphenazine, we decided to evaluate the synthetic precursors of
PIP (Scheme 1). Compound 1 showed slight antifungal activity and
the synthetic precursors 2 and 3 showed no antifungal properties.
It was observed that the presence of an electron withdrawing
group in the 2-position of the tricycle system is essential for
neuroleptic activity, so compound 4was prepared and evaluated as
antifungal agent. Neither compound 4 nor its reduced derivative 5
showed antifungal activity.
Given the fact that the length of the carbon chain joined to the
N-10 atom is very important in the physiological activity (antihis-































Chart 2. N-acyl phenothiazines prepared.
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ingly, compound 6 was found to be active against different strains
of yeasts and molds (Table 1).
Due to the activity observed in compound 6, other N-acyl (7 and
8) andN-alkyl (9) derivatives were prepared and evaluated. None of
these three compounds were active against the strains tested.
Finally, with the aim to achieve a better approximation to the
structure-activity relationship, some molecules with modifications
at different levels of compound 6 were synthesized:
a. Isosteric replacement of sulfur by oxygen atom (10).
b. Opening of the phenothiazine system to obtain the corre-
sponding dianiline (11) or diphenylthioether (15). This com-
pound was obtained from acylation of 14 with a-chloro acetyl
chloride.
c. Contraction of the heterocyclic ring (12).
The results obtained showed that none of these compounds (10,
11, 12 and 15) inhibited the growth of the fungi tested.4. Conclusion
We prepared thirteen phenothiazine derivatives and related
compounds and tested the antifungal activity of all the compounds
synthesized as well as of commercially available ones, such as PMZ
and compound 3. We found that only PMZ, PIP, and compound 6
showed interesting activity. Compound 6, the simplest of the
compounds tested, showed to be as active as antifungal agents
currently used in clinical practice. The open analogs (11 and 15) of
compound 6 were inactive. Replacement of the sulfur atom by
oxygen (10) or the elimination of the sulfur atom (12) led to loss of
activity. We can thus conclude that the phenothiazine ring is
necessary for antifungal activity, but only some pattern of substi-
tution in it led to the observed activity. Thus, despite there are not
breakpoints for the antifungal drugs, 6 could be a promising drug
since the MIC values are some comparable with those observed for
the conventional antifungal agents. Themost striking finding of this
study was the separation of the antifungal effect in compound 6
from the antihistaminic activity of PMZ and from the antipsychotic
activity of the PIP, both of which also had antifungal activities.Chart 3. N-alkyl phenothiazines prepared.5. Experimental section
5.1. Chemistry
NMR spectra were recorded (CDCl3) on a Bruker AC 300 or on an
Avance 500 spectrometers. Shifts reported are relative to the signal
of the solvent used in each case and coupling constants are
reported in Hz (s: singlet, bs: broad singlet, d: doublet, t: triplet, dd:
double doublet, dt: double triplet, m: multiplet). IR spectra were
recorded using a Perkin Elmer Spectrum One FT-IR spectropho-
tometer. High resolution mass spectra were obtained on Bruker
micrOTOF-Q II spectrometer. Microwave-assisted reactions were
carried out in a household MW oven Electrolux EH-20D. Prepara-
tive thin layer chromatography (p-TLC) was done on Merck Silica
Gel 60 GF254; and analytical TLC was performed on Merck
aluminum sheets Silica Gel 60 GF254. Commercial compounds were
purchased Aldrich Chemical Co. THF was distilled from sodium/
benzophenone. Melting points are uncorrected and were deter-
mined in a Thomas Hoover apparatus. Compound 12, whose data
do not match with those in the literature was described as new
compound.
5.1.1. General procedure for obtaining the N-acyl-derivatives
(2, 4, 6, 7, 8, 10, 11, 15)
To a solution of 10H-phenothiazine (2.62 mmol) in dry toluene
(5 mL) was added drop by drop the corresponding acyl chloride
(0.5 mL; 6.2 mmol). The reaction was irradiate with MW
(500Watts) during 10 min, then was washed with NaOH 5%
(2 5 mL) and the organic phase was dry with anhydrous Na2SO4.
Finally the solvent was remove in vacuo.
5.1.1.1. 10-(3-Chloropropionyl)-N,N-dimethyl-10H-phenothiazine-
2-sulfonamide 2. This compound was obtained as a white solid. It
was purified by p-TLC using as eluent hexane:dichloromethane (1:4
v/v). MP: 195e198 C, yield 62%. The physical and spectroscopic
data were consistent with those previously reported in the litera-
ture [22].
5.1.1.2. 10-(3-Chloropropionyl)-10H-phenothiazine 4. This com-
pound was obtained as a white solid. It was purified by p-TLC using
as eluent hexane:dichloromethane (1:3 v/v). MP: 127e130 C, yield
91%. The physical and spectroscopic data were consistent with











Chart 4. a-chloro-N-acetyl derivatives of phenoxazine, diphenylamine and carbazole.
Scheme 2. Reagents: (a) Zn/CaCl2; (b) a-chloro-acetyl chloride, MW.
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obtained as a white solid. It was purified by p-TLC using as eluent
hexane:dichloromethane (1:3 v/v). Mp: 112-114 C, yield 92%. The
physical and spectroscopic data were consistent with those previ-
ously reported in the literature [23].
5.1.1.4. 10-(Acetyl)-10H-phenothiazine 7. It was obtained as a white
solid from phenothiazine. It was purified by p-TLC using as eluent
hexane:dichloromethane (1:2 v/v). Mp: 196e199 C; yield 94.5%.
The physical and spectroscopic data were consistent with those
previously reported in the literature [24].
5.1.1.5. 10-(Chloroacetyl)-N,N-dimethyl-10H-phenothiazine-2-sulfon
amide 8. It was obtained as a yellow solid from compound 1 and
was purified by p-TLC using as eluent hexane:dichloromethane (1:4
v/v). Mp: 205 C (d), yield 50%. IR (Nujol, cm1): 1696 (C]O), 1339
(SO2N(CH3)2), 1154 (SO2N(CH3)2). 1H-NMR (400 MHz, CDCl3): d 2.71
(s, 6H, SO2N(CH3)2), 4.06 (d, J¼ 13.6 Hz, 1H, -CHHCI), 4.24 (d,
J¼ 12.8 Hz, 1H, -CHHCI), 7.27 (dt, Jo¼ 7.6 Hz Jm¼ 1.6 Hz, 1H, Ar),
7.34 (dt, Jo¼ 7.6 Hz Jm¼ 1.6 Hz, 1H, Ar), 7.44 (d, J¼ 7.6 Hz, 2H, Ar),
7.51 (d, Jo¼ 8.4 Hz, 1H, Ar), 7.58 (dd, Jo¼ 8.0 Hz Jm¼ 1.6 Hz, 1H, Ar),
7.97 (d, Jm¼ 1.6 Hz, 1H, Ar) ppm. 13C-NMR (75 MHz, CDCl3): d 165.6,
138.0, 136.9, 134.2, 129.8, 128.6, 128.2, 128.0, 126.6, 126.2, 41.7,
38.1 ppm. HRMS (ESI): calcd for C16H15O3S2N2ClNa, 405.0105,
found 405.0108.
5.1.1.6. 10-(Chloroacetyl)-10H-phenoxazine 10. It was obtained as
a white solid from phenoxazine. It was purified by p-TLC using as
eluent hexane:dichloromethane (1:2 v/v). Mp: 140-142 C, yield
91%. IR (KBr, cm1): 1675 (C]O).1H-NMR (300 MHz, CDCl3): d 4.35
(s, 2H, CH2CI), 7.14e7.28 (m, 6H, Ar), 7.58 (d, J¼ 7.7 Hz, 2H, Ar) ppm.
13C-NMR (75 MHz, CDCl3): d 41.5, 117.1, 123.7, 124.3, 127.6, 128.5,
150.9, 165.3 ppm. HRMS (ESI): calcd for C14H11O2NCl, 260.0473,
found, 260.0482.Table 1
MICs (mg/mL) values of compounds PIP, PMZ, 6 and those used as reference drugs.
Assayed fungi Evaluated drugs and calculated MICs (mg/mL)
PIP PMZ 6 AMB FCZ ITZ TBF 5FC
C. albicans 256 >512 32 0.5 2 0.125 0.5 2
C. parapsilosis 256 512 32 0.5 1 0.125 0.06 0.5
C. glabrata 256 >512 >512 0.25 1 0.25 0.06 1
C. krusei 512 256 32 0.25 64 0.06 0.06 0.5
C. guillermondii 256 512 32 1 4 0.5 0.5 1
C. neoformans 256 256 8 0.5 8 0.25 0.25 0.5
A. fumigatus >512 256 16 0.5 16 0.25 0.25 0.5
A. flavus >512 256 32 0.25 16 0.125 0.25 1
A. niger >512 256 2 0.5 16 0.125 0.125 0.5
A. terreus >512 256 16 2 16 0.125 0.06 1
C. carrionii 256 512 4 1 8 0.06 0.25 1
E. spinifera 256 256 16 1 16 0.06 0.06 2
E. oligosperma 512 256 16 1 8 0.125 0.06 4
E. xenobiotica 512 256 16 1 16 0.06 0.06 85.1.1.7. 2-Chloro-N,N-diphenylacetamide 11. This compound was
obtained as a white solid and purified by p-TLC using hexane:di-
chlorometane (1:3 v/v). Mp: 116e118 C, yield 90%. The physical
and spectroscopic data were consistent with those previously
reported in the literature [26].
5.1.1.8. 2-(N-Chloroacetylamine)-1-phenylthiobenzene 15. Compou-
nd 2-nitro-diphenylthiobenzene (13) [22] (500 mg, 2.16 mmol) was
reduced with Zn (4.6 g) and CaCl2 (155 mg) in ethanol 78%
(15.5 mL). The mixture was refluxed during 2 h. Then was filtered
and the solvent was removed in vacuo. The amine 14, obtained as
a yellow oil, was purified by p-TLC using as eluent hexane:di-
chloromethane 1:1, yield 94%. IR (film): 3468 (NH), 3371 (NH). 1H-
NMR (300 MHz), CDCI3): d 4.47 (s, 2H, NH2), 6.95 (m, 2H, Ar), 7.29
(m, 3H, Ar), 7.41 (m, 3H, Ar), 7.65 (dd, 1H, Ar) ppm. 13C-NMR
(75 MHz), CDCI3: d 114.2, 115.3,118.7, 125.4,126.4,128.9,131.1, 136.7,
137.4, 148.8 ppm.
The amine 14 was used to prepare compound 15 by the general
procedure. Compound 15 was obtained as a white solid and puri-
fied by p-TLC using hexane:dichlorometane (1:2 v/v). Mp:
65e66 C, yield 91%. IR (Nujol, cm1): 3315 (NH), 1700 (C]O), 1685
(C]N). 1H-NMR (300 MHz, CDCl3): d 4.08 (s, 2H, -CH2CI), 7.09e7.27
(m, 6H, Ar), 7.47 (t, J¼ 8.2 Hz, 1H, Ar), 7.63 (d, J¼ 7.7 Hz, 1H, Ar), 8.4
(d, J¼ 8.2 Hz, 1H, Ar), 9.5 (s, 1H, NH) ppm. 13C-NMR (75 MHz,
CDCl3): d 43.0, 120.7, 121.5, 125.2, 126.4, 127.6, 129.2, 130.8, 135.2,
136.6, 138.7, 163.9 ppm. HRMS (ESI): calcd for C14H12ONSClNa,
300.0220, found, 300.0231.
5.1.2. 10-(Chloroacetyl)-10H-carbazole 12
To a solution of carbazole (400 mg, 2.39 mmol) in dry DMF
(4 mL) was added drop by drop a-chloro acetyl chloride (0.95 ml).
The reaction was maintaining to 80 C for 2 d. The solvent was
remove in vacuo and the reaction mixture was treated with
a solution of NaOH 5% and extracted with dichloromethane
(310 mL). Then the organic layer was dried over anhydrous
Na2SO4. The solvent was removed in vacuo and the crude product
was purified by p-TLC using as eluent hexane:dichloromethane (1:1
v/v). Compound 12 was obtained as a white solid. Mp: 88e92 C,
yield 90%. IR (KBr, cm1): 1699 (C]O). 1H-NMR (500 MHz, CDCl3):
d 4.72 (s, 2H, CH2CI), 7.45 (t, J¼ 10 Hz, 2H, Ar), 7.55 (t, J¼ 10 Hz, 2H,
Ar), 8.03 (d, J¼ 10 Hz, 2H, Ar), 8.2 (d, J¼ 10 Hz, 2H, Ar) ppm. 13C-
NMR (75 MHz, CDCl3): d 44.9, 116.2, 120.0, 124.4, 126.7, 127.6, 137.9,
165.6 ppm. HRMS (ESI): calcd for C14H11ONCl, 244.0524, found,
244.0530.
5.1.3. General procedure for obtaining the N-alkyl-derivatives (5, 9)
Borane gas was generated from a mixture of NaBH4 (1.6 g) in
diethylene glycol dimethyl ether (6 mL) and trifluoroboroetherate
(5.4 mL) was bubbled on the corresponding N-acyl-derivative
(0.91 mmol) in dry THF (10 mL). Then the solution was stirred
during 72 h at room temperature. After that, the solution was
adjusted to pH¼ 8 by slowly adding of 1N HCl and the product was
G.P. Sarmiento et al. / European Journal of Medicinal Chemistry 46 (2011) 101e105 105extracted with several portions of dichloromethane. The organic
extract was dried with anhydrous Na2SO4 and the solvent was
removed in vacuo and was purified by p-TLC.
5.1.3.1. 10-(3-Chloropropyl-)-10H-phenothiazine 5. It was obtained
as a green solid and purified by p-TLC using hexane:di-
chlorometane (1:1 v/v). Mp: 60e61 C, yield 88%. IR (KBr, cm1):
1284 (CeN), 1252 (CeN). 1H-NMR (300 MHz, CDCl3): d 2.24 (m, 2H,
CeCH2eC), 3.68 (t, J¼ 6.2 Hz, 2H, eNeCH2eC), 4.11 (t, J¼ 6.6 Hz,
2H, eCH2eCI), 6.93 (m, 4H, Ar), 7.19 (m, 4H, Ar) ppm. 13C-NMR
(125 MHz, CDCl3): d 29.6, 42.4, 44.0, 115.6, 122.8, 125.7, 127.3, 127.6,
145.0 ppm. HRMS (ESI): calcd for C15H14NSClNa, 298.0427, found,
298.0428.
5.1.3.2. 10-(2-Chloroetyl)-10H-phenothiazine 9. This compound
was obtained as a green solid and was purified by p-TLC using as
eluent hexane:dichloromethane (1:1 v/v). Mp: 94e95 C, yield 85%.
The physical and spectroscopic data were consistent with those
previously reported in the literature [25].
5.2. Antifungal activity
Compounds described above (1e12 and 15) were evaluated by
diffusion methodology as screening. From all, halo of inhibitionwas
observed only for PIP, PMZ, compound 1 and 6. Then, the antifungal
activity of these four compounds and several antifungal agents in
clinical use against yeasts and molds were evaluated following the
CLSI (Clinical and Laboratory Standards Institute) guidelines
(formerly NCCLS), document M27A2 and M38A2 [28,29]. The drugs
evaluated were: amphotericin B (AMB), itraconazole (ITZ), fluco-
nazole (FCZ), terbinafine (TBF), flucytosin (5FC), PIP, PMZ,
compound 1 and compound 6. The assayed yeasts were: Candida
albicans, Candida parapsilosis, Candida glabrata, Candida krusei,
Candida guillermondii, Cryptococcus neoformans. The filamentous
fungi included: Aspergillus fumigates, Aspergillus flavus, Aspergillus
niger, Aspergillus nidulans, Aspergillus terreus, Cladophialophora
carrionii and black yeasts: Exophiala spinifera, Exophiala oligo-
sperma, Exophiala xenobiotica. Briefly fungi were growth onto
Saboureaud glucose agar, during 2 days for yeasts and up to 7 days
for the molds. For each drug, stock solutions were prepared and
diluted in the appropriate solvent to be inoculated into 96-well-
flat-bottom micro titer plates. Fungi inoculum was prepared
according with the CLSI and inoculated into the plates. Final inoc-
ulums for yeasts was 0.5e5103 CFU/ml, and for filamentous fungi
0.5e5104 CFU/ml. After incubation at 30 C, spectrophotometer
and visual reading were determined in order to obtain the minimal
inhibitory concentration (MIC) for each strain and each drug.
Compound 1 was tested against all strains. Halo of inhibition
was observed by diffusion test, but, when microdilution was per-
formed, all strains showed MICs >512 ug/ml, indicating lacking of
activity. Activity was observed for PIP and PMZ at concentrations
ranged from 128 to 512 ug/ml, with the exception of Aspergillusspecies for PIP showed MIC> 512 ug/ml. Interesting was to observe
the higher activity of compound 6 compared with those described
above. For this drug the range was from 2 to 32 ug/ml, except for C.
glabrata, for which MIC of >512 ug/ml was detected. All data is
summarized in Table 1.Acknowledgement
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